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Abstract
Introduction: Allergic diseases could play a role of a predisposing factor for coronavirus dis-
ease 2019 (COVID-19). The aim of this study was to investigate allergic comorbidity and its 
association in COVID-19 patients.
Methods: Demographic data, clinical manifestations, laboratory reports, and radiologic find-
ings, together with underlying comorbidity of patients, were studies. Allergic diseases were 
identified by using the standard GA2LEN questionnaire. The severity of COVID-19 was assessed 
by a visual analog scale (VAS) and an intensive care unit (ICU) report.
Results: Out of 400 COVID-19 patients admitted in the hospital, 158 (39.5%) presented with 
different allergic diseases, and a reverse association was observed between having allergic 
comorbidity and severity of COVID-19 infection (P = 0.005, relative risk = 0.96; 95% Confidence 
Interval (95% CI): 0.77–1.19). The respective frequency of asthma, allergic rhinitis (AR), chronic 
rhinosinusitis (CRS), atopic dermatitis, chronic urticaria, and food or drug allergy was 7.3%, 
16%, 1.8%, 5%, 10% and 13.3%. Significantly, only AR was reversely associated with the severity 
of COVID-19 (P = 0.02, relative risk = 0.45; 95% CI: 0.77–1.19). Additionally, 43% of the patients 
presented hypoxemia, and 93.5% had chest CT scan involvement. Interestingly, patients with 
allergic diseases had significantly lower hypoxemia and chest CT involvement as compared 
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Materials and methods
Data collection of the COVID-19 patients
This case series study was conducted in the general hospi-
tal affiliated to the Bushehr University of Medical Sciences 
(BPUMS), Iran. All the 400 patients tested positive for SARS-
CoV-2 infection (identified by using Reverse Transcriptase-
Polymerase Chain Reaction [RT-PCR] test) participated 
in this study. The patients were split in three groups: 68 
patients were admitted in ICU, 270 were admitted in wards, 
and 62 were treated as OPD patients. Demographic data 
and clinical manifestations of the COVID-19 patients, includ-
ing fever, general condition, respiratory, and gastrointesti-
nal (GI) indications were recorded by trained medical staff 
in a questionnaire. The severity of COVID-19 was assessed 
at the time of admission using VAS. Patients admitted in 
the ICU were considered as severe cases. Laboratory find-
ings and computed tomographic (CT) scan of the chest of 
each patient were obtained and evaluated from the elec-
tronic medical record system of the hospital. In addition, 
we assessed other underlying diseases, such as diabetes 
mellitus, hypertension, cardiovascular, brain, liver, thy-
roid, and kidney disorders of the patients by self-reporting. 
This study was approved by the Ethics Committee of the 
Bushehr University of Medical Sciences, Bushehr, Iran (ethi-
cal approval code: IR.BPUMS.REC.1399.083).
Identification of allergic diseases in COVID-19 
patients
For identification and epidemiological investigation of aller-
gic diseases in the COVID-19 patients, we used the standard 
questionnaire of the Global Allergy and Asthma European 
Network (GA2LEN).15 For this questionnaire, details of all 
allergic disorders, such as AR, allergic rhinoconjunctivi-
tis (ARC), chronic rhinosinusitis, asthma, chronic urticaria 
(CU), atopic dermatitis (AD), and food or drug allergy, were 
obtained as self-reported by the patients based on the 
questions about the diseases as stated in the GA2LEN ques-
tionnaire. Furthermore, other physicians also diagnosed 
the stated diseases, including COPD.
Statistical analysis
Descriptive statistics such as mean value and standard 
deviation (SD) of laboratory findings and the frequency 
distribution of age groups, gender, smoking status, allergic 
diseases, underlying diseases, and COPD in the COVID-19 
patients were determined. Association between 
Introduction
Coronavirus disease 2019 (COVID-19), caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
has rapidly spread globally, with sharp increase in Iran and 
some other countries. The disease causes severe pneumo-
nia and other complications, including death in severely 
affected patients.1,2 Clinical manifestations of the COVID-19 
infection reported so far include headache, fever, cough, 
shortness of breath, and breathing difficulties as well as 
taste and smell dysfunction. Generally, nasal symptoms 
and sore throat could be the result of viral airway infec-
tion, but in some severe cases, the infection could lead to 
pneumonia, SARS, renal failure, and death.3–6
It has been reported that COVID-19 might result in 
severe conditions because of different comorbidities, 
including hypertension (HTN), chronic obstructive pulmo-
nary disease (COPD), diabetes mellitus (DM), cardiovas-
cular disease, and obesity.7 A study conducted in China 
on the clinical characteristics of 1099 COVID-19 patients 
has demonstrated that 15.7% of patients had severe 
pneumonia.8
Allergic respiratory diseases, especially allergic rhinitis 
(AR), chronic rhinosinusitis (CRS), and asthma (AS), affect a 
large global population, and because of chronic inflamma-
tory characteristics of these diseases, they may influence 
susceptibility to the SARS-CoV-2 infection and could be a 
cause of severe COVID-19.9,10 Presently, only few data are 
available to confirm a specific increased risk for COVID-19 in 
patients with underlying allergic diseases. However, another 
study from China has recently reported that these diseases 
could not be considered as risk factors for severe COVID-19 
disease.5 Moreover, some data have depicted that the prev-
alence of asthma in the COVID-19 patients in China was less 
than 1%11 whereas in the United States, prevalence of asthma 
was reported as 7–17%.12,13 Therefore, there may exist a risk 
for exacerbation of allergic diseases, especially asthma, 
triggered by SARS-CoV-2 as a respiratory viral infection.14
Owing to the epidemic status of COVID-19 in Iran, many 
studies have reported the clinical features of the disease; 
however, as far as the present study is concerned, there 
has been no study that assessed the frequency of allergic 
diseases and their association with COVID-19. Therefore, 
this study investigated the clinical and laboratory charac-
teristics of COVID-19 patients admitted in wards, intensive 
care unit (ICU), and out patients department (OPD), associ-
ating severe and nonsevere conditions based on ICU admis-
sion and visual analog scale (VAS). Moreover, the frequency 
of allergic and other underlying diseases as associated 
comorbidity was determined in patients having COVID-19. 
Finally, association between COVID-19 and allergic diseases 
as a risk factor was examined.
Conclusion: The results of this study established that allergic diseases were not determined to 
be a predisposing factor for the severe acute respiratory syndrome (SARS) due to coronavirus 
2 (SARS-CoV-2) infection. Significantly, AR patients developed mild clinical manifestations of 
COVID-19 and admitted to ICU as compared to non-AR patients.
© 2021 Codon Publications. Published by Codon Publications.
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and 68 (17%) were admitted in wards and ICU, respectively. 
Demographic and clinical data of the patients are provided 
in Table 1.
Clinical manifestations of COVID-19 patients
The most common clinical manifestations of the patients 
were chest tightness/dyspnea (78.5%), fatigue (77.3%), 
cough (69%), and fever (64%). Severity of the patient’s clin-
ical manifestations based on self-reported VAS was mild 
(41%), moderate (47%), and severe (12%). There was an 
association between having fever (P = 0.005), chest tight-
ness/dyspnea (P < 0.001), severe headache (P = 0.01), anos-
mia/hyposmia (P < 0.001), and GI manifestations (P < 0.001) 
and treatment of OPD patients. On the other hand, there 
was an association between having cough (P = 0.01), chest 
tightness/dyspnea (P = 0.01), anosmia/hyposmia (P = 0.01), 
and diarrhea (P = 0.01) and admission in wards (Table 2).
demographic characteristics and clinical data of the 
patients was evaluated using Chi-square test. Moreover, 
Chi-square test was also used for assessing the correlation 
between allergic diseases, COPD, and other underlying 
comorbid diseases and the COVID-19 manifestations and its 
severity (admission in ICU and VAS). Differences in labora-
tory findings were compared using two independent t-tests, 
and P < 0.05 was considered statistically significant. All sta-
tistical analyses were performed using IBM SPSS Statistics 
for Windows, version 22 (IBM Corp., Armonk, NY, USA).
Results
In this study, 400 COVID-19 patients (51.2% males and 
48.8% females) were enrolled. The mean (SD) age of all 
the patients was 49.2 with a range of 17–92 years. Of the 
400 patients, 62 (15.5%) were OPD patients, and 270 (67.5%) 






Non-ICU admissions (Outpatients 
and wards admission) N (%) P-value
Males 205 (51.2) 40 (10) 165 (41.2) 0.1
Females 195 (48.8) 28 (7) 167 (58.8)
Age group (years)
 <30 45 (11.2) 4 (1) 41 (10.2) 0.00
 30–39 83 (20.8) 10 (2.5) 73 (18.2)
 40–49 88 (22) 9 (2.2) 79 (19.7)
 50–59 65 (16.3) 9 (2.2) 56 (14)
 ≥60 119 (29.7) 35 (8.7) 84 (21)
Fever 256 (64) 44 (17.2) 212 (82.8) 0.5
Cough 276 (69) 47 (17) 229 (83) 0.5
Fatigue 309 (77.3) 46 (14.9) 263 (83.5) 0.03
Chest tightness/dyspnea 314 (78.5) 61 (19.4) 253 (80.6) 0.008
Severe headache 160 (40) 18 (11.3) 142 (88.8) 0.008
Anosmia/hyposmia 51 (12.8) 3 (5.9) 48 (94.1) 0.001
Nausea and vomiting 126 (31.5) 19 (15.1) 107 (84.9) 0.2
Diarrhea 88 (22) 10 (11.4) 78 (87.6) 0.07
Abdominal pain/dyspepsia 82 (20.5) 8 (9.8) 84 (90.2) 0.03
Anorexia 225 (56.3) 29 (12.9) 196 (87.1) 0.01
Oral aphthous 20 (5) 3 (15) 17 (85) 0.5
Smoking 109 (27.3) 22 (5.5) 87 (21.7) 0.05
Allergic diseases (self-reported)
 Allergic rhinitis 64 (16) 5 (7.8) 59 (92.2) 0.02
  Allergic rhinoconjunctivitis 52 (13) 5 (9.6) 47 (90.4) 0.08
 Chronic rhinosinusitis 7 (1.8) 0 7 (100) 0.2
  Asthma 29 (7.3) 2 (6.9) 27 (93.1) 0.09
  Atopic dermatitis 20 (5) 1 (5) 19 (95) 0.1
  Chronic urticaria 40 (10) 3 (7.5) 37 (92.5) 0.06
Total 158 (39.5) 16 (10.8) 142 (89.2) 0.005
Comorbid diseases (self-reported)
 Hypertension 99 (24.8) 30 (30.3) 69 (69.7) 0.00
 Diabetes mellitus 78 (19.5) 17 (21.8) 61 (78.2) 0.1
 Thyroid disorders 26 (6.5) 6 (21.3) 20 (76.9) 0.2
 Fatty liver 108 (27) 23 (21.3) 85 (78.7) 0.1
 Cardiovascular disorders 65 (16.3) 22 (33.8) 43 (66.2) 0.00
 Brain diseases 25 (6.3) 11 (44) 14 (56) 0.001
 Kidney diseases 32 (8) 9 (28.1) 23 (71.9) 0.07
Total 260 (65) 53 (20.4) 207 (79.6) 0.009
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asthma and admission in wards (P = 0.4) or OPD treatment 
(P = 0.1). Importantly, only two patients (0.5%) with asthma 
had acute clinical manifestations of COVID-19 and admitted 
in the ICU. In addition, of the total number of patients with 
COVID-19, 64 (16%) had AR; of these 22 (5.5%) were treated 
as outpatients and 23 (5.7%) were admitted in wards 
(self-reported). Furthermore, a relationship was observed 
between having AR and OPD treatment (P = 0.002); how-
ever, no relationship was established between having AR 
and admission in wards (P = 0.1). We had only two patients 
with CRS and nasal polyp (CRSwNP). The frequency of hav-
ing food or drug allergy and COPD was 13.3% and 6.8%, 
Allergic comorbidity in COVID-19 patients
The total frequency of allergic comorbidity in COVID-19 
patients was 158 (39.5%), and it was reversely associated 
with the severity of COVID-19 as required for admission 
in ICU (P = 0.005, relative risk = 0.96; 95% CI: 0.25–0.81). 
Moreover, a relationship was established between hav-
ing allergic comorbidity and OPD treatment for COVID-19 
(P = 0.02, relative risk = 1.7; 95% CI: 1.03–2.8). Frequency of 
allergic diseases in COVID-19 patients is shown in Figure 1. 
The number of patients having asthma was 29 (7.3%). 
However, no relationship was established between having 
Table 2 Clinical manifestations and paraclinical data of COVID-19 patients with or without allergic comorbidity.
Variable
Patients with allergic 
comorbidity, N (%)
Patients without allergic 
comorbidity, N (%) P-value
Gender 0.00
 Male 63 (30.7) 142 (69.3)
 Female 95 (48.7) 100 (51.3)
Age group (years) 0.02
 <30 23 (51.1) 22 (48.9)
 30–39 42 (50.6) 41 (49.4)
 40–49 35 (39.8) 53 (60.2)
 50–59 22 (33.8) 43 (66.2)
 ≥60 36 (30.5) 82 (69.5)
Fever 104 (65.8) 152 (62.8) 0.3
Cough 112 (70.9) 164 (67.8) 0.2
Fatigue 126 (79.7) 153 (75.6) 0.2
Chest tightness/dyspnea 126 (79.7) 188 (77.7) 0.3
Severe headache 75 (47.5) 85 (35.1) 0.009
Anosmia/hyposmia 32 (20.3) 19 (7.9) 0.00
Nausea and vomiting 70 (44.3) 56 (23.1) 0.00
Diarrhea 37 (23.4) 51 (21.1) 0.3
Abdominal pain/dyspepsia 36 (22.8) 46 (19) 0.2
Anorexia 94 (59.5) 131 (54.1) 0.1
Oral aphthous 11 (7) 9 (3.7) 0.1
Severity of symptoms 0.3
(VAS; self-reported)
 Mild 70 (44.3) 94 (38.8)
 Moderate 73 (46.2) 115 (47.5)
 Severe 15 (9.5) 33 (13.6)
WBC (total number) 6900 ± 313 7200 ± 283 0.4
 Neutrophil (%) 73.3 ± 12 74.4 ± 12 0.3
 Lymphocyte (%) 19.5 ± 9.8 18.4 ± 10.3 0.3
 Platelets (n) 215000 ± 8000 212000 ± 5000 0.8
ESR (mm/h) 45.1 ± 2.1 46.6 ± 1.7 0.5
CRP (mg/L) 61 ± 3.7 66.1 ± 2.9 0.2
SGOT (IU/L) 42.7 ± 2.7 44.8 ± 2.3 0.5
SGPT (IU/L) 45.5 ± 3 46.2 ± 3.1 0.8
AP (IU/L) 202.3 ± 11.3 198.2 ± 5.2 0.7
Hypoxemia (SpO2 < 93%) 54 (34.2) 118 (49) 0.002
CT, chest involvement 0.003
 No 18 (11.5) 8 (3.3)
 Mild 24 (15.3) 39 (16.3)
 Moderate 68 (43.3) 92 (38.8)
 Severe 47 (29.9) 102 (42.3)
WBC: white blood cells; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SGOT: serum glutamic-oxaloacetic transami-
nase; SGPT: serum glutamic-pyruvic transaminase; AP: alkaline phosphatase.
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present study, 400 patients, including ward/ICU admissions 
and OPD patients, infected with SARS-COV-2 were exam-
ined for allergic diseases.
The total frequency of allergic comorbidity among 
COVID-19 patients was 39.5%, and it was reversely associ-
ated with the severity of COVID-19 manifestations in such 
a manner that these patients had significantly lower admis-
sions in the ICU than the patients with no signs of allergy. 
However, there was a significant association between hav-
ing allergic comorbidity and OPD treatment of COVID-19. 
Several studies having assessed the association between 
respiratory viral infection, such as respiratory syncytial 
virus (RSV) and exacerbation of respiratory allergic dis-
eases, reported that viral infections of the respiratory tract 
are associated with exacerbation of diseases.16,17 It was con-
firmed that angiotensin-converting enzyme 2 (ACE2) and 
transmembrane protease serine 2 (TMPRSS2), which are 
expressed in airway epithelial cells, were identified as the 
main receptors of SARS-CoV-2. Moreover, other studies have 
reported that patients with allergic respiratory diseases 
have downregulated ACE2 expression in nasal and bronchial 
epithelial cells. Further, another study has established that 
use of inhaled corticosteroids (ICS) was associated with the 
downregulation of both ACE2 and TMPRSS2 receptors.18–20 
Taken together, despite having the presence of allergic 
diseases in a large proportion of general population; these 
were not determined to be a predisposing factor for the 
SARS-CoV-2 infection.
In addition, our study established that asthma was 
present in 7.3% of the patients, including admitted and OPD 
patients. According to our previous study, the prevalence 
of asthma in the region was 10% in general population.21 
However, in the present study, we noticed that frequency 
respectively. It is important to note that no relationship 
was demonstrated between having comorbidity of atopic 
dermatitis (P = 0.02), chronic urticaria (P = 0.02), or COPD 
(P = 0.002) and OPD treatment.
Moreover, in the past 12 months, 3.5% of the patients 
had reported wheezing or whistling sound in the chest, 
2.5% had shortness of breath, 2.5% had an attack of cough, 
and 2.5% had sputum in the chest. Further, a relationship 
was demonstrated between having a cough attack and both 
OPD treatment and patients admitted in wards (P = 0.04 
and 0.01, respectively). Only 1% of the patients reported 
reduced feeling or loss of smell in the past 12 months.
It was observed that 54 (34.2%) of the total patients 
with allergic comorbidity had hypoxemia. A significant 
difference was observed between having allergic comor-
bidity and lower presence of hypoxemia during COVID-19 
(P = 0.002, relative risk = 0.54; 95% CI: 0.35–0.81). In addi-
tion, 94 (23.5%) of the total patients had both allergic 
and other underlying diseases. In addition, no associa-
tion was observed between having both allergy and some 
above-mentioned underlying diseases and severity of 
COVID-19 (P > 0.05). The frequency of underlying diseases 
in COVID-19 patients is shown in Table 1. Finally, 40 (10%) of 
the total patients were smokers and have allergic diseases 
simultaneously. However, this condition was not associated 
with the severity of COVID-19 (P > 0.05).
Discussion
To the best of our knowledge, this is the first study con-
ducted in Iran considering patients with COVID-19 and its 
association with the comorbidity of allergic diseases. In the 
Figure 1. The frequency of allergic diseases in COVID-19 patients. AR: Allergic rhinitis; ARC: Allergic rhinoconjunctivitis; CRS: 
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patients, and the number of males with COVID-19 admit-
ted in ICU was higher than females (10% vs. 7%, respec-
tively). In addition, males were significantly less likely to 
present allergic diseases than females (30.7% vs. 48.7%, 
respectively). Further, the data established that most of 
the patients frequently referred with COVID-19 were aged 
60 years and above, and more admissions in ICU were made 
from this age group than other groups. In addition, the 
highest frequency of allergic diseases was determined in 
the age group of 30–35 years.4,5,23 Therefore, we conclude 
that allergic diseases which are more frequent in younger 
age groups could be due to factors that alleviate the sever-
ity of COVID-19 symptoms. However, further investigations 
are required to determine why these conditions lead to 
better COVID-19-related outcomes.
The most common symptoms reported in the patients 
of our study were chest tightness/dyspnea, fatigue, cough, 
and fever. On the other hand, the study from China has 
reported that fever, cough, and fatigue were the prior 
symptoms determined in COVID-19 patients.5 Therefore, 
the frequency of COVID-19 symptoms may vary with diver-
sity in populations.
Limitations
There were several limitations to our study. The first was 
that since some of the data were obtained from the elec-
tronic medical record system of the hospital, we were lim-
ited to performing specific tests, such as immunoglobulin E 
(IgE), for more accurate diagnosis of allergic diseases. The 
second limitation was that critically ill patients admitted 
in ICU and wards were less cooperative in answering the 
related questions.
Conclusion
The present study established that allergic diseases and 
asthma, present in a large proportion of general popula-
tion, were not predisposing factors for SARS-CoV-2 infec-
tion. Interestingly, the patients with AR developed mild 
symptoms of COVID-19, and significantly fewer were admit-
ted in ICU as compared to non-AR patients. Moreover, aller-
gic conditions as underlying diseases in COVID-19 patients 
were not associated with the severity of the disease or 
the number of admissions in ICU. Finally, the data revealed 
that more males were affected by COVID-19 and admitted 
in ICU compared to females.
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of asthma among the admitted COVID-19 patients was 5.2%. 
Therefore, our data revealed that asthmatic patients are 
less likely to develop COVID-19 as compared to general pop-
ulation. However, a US study conducted on 1526 patients 
identified with COVID-19 has reported that 14.4% of the 
patients had asthma. Other recent studies from the United 
States have demonstrated that the prevalence of asthma 
in the admitted COVID-19 patients was 7–17%.7,13,14 Contrary 
to the present study, a study conducted in China did not 
identify any asthmatic case among 140 COVID-19 patients.5 
Thus, the controversy over prevalence of asthma could 
be related to geographic variations or different methods 
of assessment and epidemiologically identified asthma. In 
addition, our findings were in line with a US study which 
evidenced that there was no association between asthma 
comorbidity and the severity of COVID-19 as required for 
ICU care.14
The frequency of other allergic diseases such as AR, 
chronic rhinosinusitis, atopic dermatitis, chronic urti-
caria, and food or drug allergy in COVID-19 patients was 
16%, 1.8%, 5%, 10% and 13.3%, respectively. In addition, 
the present data depicted that the severity of COVID-19 
required for admission in ICU was significantly lower in AR 
patients, which is not in agreement with the outcome of 
Chinese study pointing no allergic disease.5
We also assessed comorbidities of both allergic and 
other underlying diseases such as diabetes mellitus, 
hypertension, cardiovascular, brain, liver, thyroid, and 
kidney disorders in COVID-19 patients. Interestingly, our 
data demonstrated that 23.5% of COVID-19 patients had 
allergic and other underlying diseases as comorbidities. 
Furthermore, the above-mentioned comorbidities were not 
associated with the severity of COVID-19. However, recent 
studies have demonstrated that some underlying diseases 
such as diabetes mellitus and cardiovascular diseases are 
the risk factors for COVID-19.7,22 The result of our study sug-
gested that comorbidity of allergic diseases and the use of 
corticosteroids may be downregulating ACE2 and TMPRSS2 
receptors, leading to a decrease in the risk of SARS-CoV-2 
infection in patients with underlying diseases.19 In addition, 
the present study has established that although 10% of the 
patients had allergic diseases and smoking habit simulta-
neously, they depicted no association with the severity of 
COVID-19. Moreover, COPD as an underlying disease wit-
nessed in 6.8% of the patients was not associated with the 
severity of COVID-19. In the study conducted in China, only 
two (1.4%) of the 140 patients were reported with COPD, 
which confirmed that COPD played a minor role in the 
exacerbation of COVID-19.5
Noticeably, the results of the present study indicated 
that 93.5% of COVID-19 patients had involvement of chest 
CT scan, and 43% of them presented hypoxemia. Zhang et 
al. have reported the presence of bilateral ground-glass 
and patchy opacity in CT scan or X-ray in 89.6% of COVID-19 
patients.5 Interestingly, our data indicated that patients 
with allergic diseases had significantly lower hypoxemia 
and involvement of chest CT.
The data from the present study was in line with other 
studies expressing that males were more affected with 
COVID-19 compared to females among admitted and OPD 
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